摘要
基因工程和药物生物技术的最新进展已使有效地提供治疗性蛋白来打击危及生命的疾病成为可能。这些进步增加了药物市场中的治疗性蛋白的意义,但他们的治疗传递到有针对性的位点以达到预期的治疗效果仍然是一个主要障碍。在大多数情况下,大多数的治疗性蛋白通常是通过口服途径吸收,会遇到许多问题,特别是酶的降解,溶解性差和非线性药代动力学等。除了这条路径,许多其他的路径,如粘膜,鼻内,阴道内,肺和透皮也被用于治疗性蛋白的传递。为了使这些治疗蛋白安全的避开酶降解而提高他们的治疗效果,以保证最小的副作用而有效地提供治疗性蛋白的靶点,一些策略已被设计和研究用于各种治疗性的方案中。在这篇文章中,我们已经全面总结了最近的进步和发展,通过侵入性和/或非侵入性的路线来研究这些治疗性蛋白的传递系统。
关键词: 侵入性递送系统;非侵入性递送系统;递送策略。
Current Drug Targets
Title:Delivery of Therapeutic Proteins: Challenges and Strategies
Volume: 17 Issue: 10
Author(s): Kanwal Rehman, Muhammad Sajid Hamid Akash, Bushra Akhtar, Muhammad Tariq, Abid Mahmood, Muhammad Ibrahim
Affiliation:
关键词: 侵入性递送系统;非侵入性递送系统;递送策略。
摘要: Recent advances in genetic engineering and pharmaceutical biotechnology have made possible to combat life-threatening diseases with efficient delivery of therapeutic proteins. These advancements have increased the significance of therapeutic proteins in pharmaceutical market, but their therapeutic delivery to the targeted site is still a major obstacle to achieve desired therapeutic outcomes. In most cases, majority of the therapeutic proteins are usually administered via oral routes which encounter many problems notably enzymatic degradation, poor solubility and nonlinear pharmacokinetics. Besides this route, many other routes like mucosal, intra-nasal, intra-vaginal, pulmonary and transdermal have also been used for the delivery of therapeutic proteins. In order to keep these therapeutic proteins safe from enzymatic degradation and improve their therapeutic efficacy, several strategies have been designed and investigated various therapeutic delivery routes for efficient delivery of therapeutic proteins to the targeted site with minimal side effects. In this article, we have comprehensively summarized the recent advances and developments that have been adopted for delivery systems of these therapeutic proteins via invasive and/or non-invasive routes.
Export Options
About this article
Cite this article as:
Kanwal Rehman, Muhammad Sajid Hamid Akash, Bushra Akhtar, Muhammad Tariq, Abid Mahmood, Muhammad Ibrahim , Delivery of Therapeutic Proteins: Challenges and Strategies, Current Drug Targets 2016; 17 (10) . https://dx.doi.org/10.2174/1389450117666151209120139
DOI https://dx.doi.org/10.2174/1389450117666151209120139 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science Organ-Level Tissue Engineering Using Bioreactor Systems and Stem Cells: Implications for Transplant Surgery
Current Stem Cell Research & Therapy Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Rationale for New Drugs Targeting the Tissue Microenvironment in Patients with HCC
Current Pharmaceutical Design A Novel Approach to the Old Issue of Ischemic Nephropathy
Current Vascular Pharmacology Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
Current Hypertension Reviews Improved Anti-inflammatory Activity and Potential Cytoprotective Properties of Tolfenamic Acid, Naproxen and Indomethacin Derivatives
Letters in Drug Design & Discovery Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued) Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Current Neurovascular Research Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
Current Pharmaceutical Design